Compare
CorMedix Inc. vs Evolus, Inc. vs Xeris Biopharma Holdings, Inc. vs MannKind Corp
| Latest fiscal year | CorMedix Inc. CRMD | Evolus, Inc. EOLS | Xeris Biopharma Holdings, Inc. XERS | MannKind Corp MNKD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $311.71M | $297.18M | $291.85M | $348.97M |
| Revenue growth (YoY) | +617.0% | +11.6% | +43.7% | +22.2% |
| Gross margin | 88.5% | 66.3% | n/a | 92.3% (computed) |
| Operating margin | 48.2% | -11.0% | 8.5% | 11.1% |
| Net margin | 52.3% | -17.4% | 0.2% | 1.7% |
| Net income | $163.06M | -$51.64M | $554.0K | $5.86M |
| EPS (Diluted) | $2.04 | -$0.80 | $0.00 | $0.02 |
| Operating cash flow | $175.05M | -$42.27M | $28.63M | $18.25M |
| Free cash flow | $172.79M | -$45.71M | n/a | $13.69M |
| Cash & equivalents | $144.84M | $53.83M | $111.04M | $74.88M |
| Total assets | $826.14M | $225.87M | $383.53M | $792.18M |
| Total liabilities | $420.83M | $248.97M | $369.84M | $843.20M |
| Shareholders' equity | $405.31M | -$23.11M | $13.69M | -$51.02M |
| Return on year-end equity | 40.2% | n/a | 4.0% | n/a |
| Shares outstanding | 79.26M | 65.01M | 166.22M | 307.83M |
Revenue, most recent five fiscal years
| Fiscal year | CorMedix Inc. | Evolus, Inc. | Xeris Biopharma Holdings, Inc. | MannKind Corp |
|---|---|---|---|---|
| Latest | $311.71M Ended 2025-12-31 | $297.18M Ended 2025-12-31 | $291.85M Ended 2025-12-31 | $348.97M Ended 2025-12-31 |
| 1 year earlier | $43.47M Ended 2024-12-31 | $266.27M Ended 2024-12-31 | $203.07M Ended 2024-12-31 | $285.50M Ended 2024-12-31 |
| 2 years earlier | n/a | $202.09M Ended 2023-12-31 | $163.91M Ended 2023-12-31 | $198.96M Ended 2023-12-31 |
| 3 years earlier | $65.4K Ended 2022-12-31 | $148.62M Ended 2022-12-31 | $110.25M Ended 2022-12-31 | $99.77M Ended 2022-12-31 |
| 4 years earlier | $190.9K Ended 2021-12-31 | $99.67M Ended 2021-12-31 | $49.59M Ended 2021-12-31 | $75.44M Ended 2021-12-31 |